{"id":690181,"date":"2022-09-29T08:04:44","date_gmt":"2022-09-29T12:04:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/"},"modified":"2022-09-29T08:04:44","modified_gmt":"2022-09-29T12:04:44","slug":"selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/","title":{"rendered":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions"},"content":{"rendered":"
\n

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR\u00ae platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells. The leukocyte integrins were found to be part of a larger family of integrins involved in fundamental cell interactions related to embryonic development, hemostasis and other processes and discovered by Lasker Award co-winners Dr. Richard Hynes and Dr. Erkki Rouslahti. Selecta\u2019s Chief Scientific Officer, Kei Kishimoto, Ph.D., was a key contributor to this foundational work during his time in Dr. Springer\u2019s lab.<\/p>\n

\u201cTim\u2019s contributions to the field of immunology are truly monumental,\u201d said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta Biosciences. \u201cOur increased understanding of the principles governing complex immune cell interactions have opened vast opportunities for therapeutic development, and Selecta continues to benefit tremendously from Tim\u2019s scientific insights and advice.\u201d<\/p>\n

The Lasker Awards program was created to highlight fundamental biological discoveries and clinical advances that improve human health, and to draw attention to the importance of public support of science.<\/p>\n

\n About\u00a0Selecta Biosciences, Inc.<\/strong>
\n
Selecta Biosciences Inc.\u00a0(NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR\u00ae<\/sup>\u00a0platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body\u2019s natural self-tolerance in autoimmune diseases.\u00a0Selecta\u00a0has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases.\u00a0Selecta Biosciences\u00a0is headquartered in the\u00a0Greater Boston\u00a0area. For more information, please visit\u00a0www.selectabio.com<\/a>.<\/p>\n

\n Selecta Forward-Looking Statements<\/strong>
\n
Any statements in this press release about the future expectations, plans and prospects of\u00a0Selecta Biosciences, Inc.\u00a0(the \u201cCompany\u201d), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company\u2019s product pipeline to treat chronic refractory gout, MMA, IgAN, other autoimmune diseases, lysosomal storage disorders, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the anticipated timing or the outcome of the FDA\u2019s review of the Company\u2019s regulatory filings, the Company\u2019s and its partners\u2019 ability to conduct its and their clinical trials and preclinical studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company\u2019s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company\u2019s technology to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company\u2019s ability to grow its strategic partnerships, enrollment in the Company’s clinical trials and the Company’s plans with respect to areas affected by geopolitical conflict and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201chypothesize,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company\u2019s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the Company\u2019s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company\u2019s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company\u2019s recurring losses from operations and negative cash flows, substantial fluctuation in the price of its common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Annual Report on Form 10-K, as supplemented by subsequent Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the\u00a0Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company\u2019s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release except as required by law.<\/p>\n

\n For investors:<\/strong>
\n
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com<\/a><\/p>\n

\n For media:\u00a0<\/strong>
\n
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-813-767-7801
bleigh@lifescicomms.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR\u00ae platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells. The leukocyte integrins were found to be part of a larger family of integrins involved in fundamental cell interactions related to embryonic development, hemostasis and other processes and discovered by … <\/p>\n

Continue reading “Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690181","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSelecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR\u00ae platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells. The leukocyte integrins were found to be part of a larger family of integrins involved in fundamental cell interactions related to embryonic development, hemostasis and other processes and discovered by … Continue reading "Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:04:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions\",\"datePublished\":\"2022-09-29T12:04:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/\",\"name\":\"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==\",\"datePublished\":\"2022-09-29T12:04:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/","og_locale":"en_US","og_type":"article","og_title":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk","og_description":"WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR\u00ae platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, extends its congratulations to its board of directors member, Timothy Springer, Ph.D., who yesterday won the Albert Lasker Basic Medical Research Award for his seminal discovery of integrin adhesion molecules that regulate trafficking, cell-cell interactions, and effector functions of lymphocytes and other immune cells. The leukocyte integrins were found to be part of a larger family of integrins involved in fundamental cell interactions related to embryonic development, hemostasis and other processes and discovered by … Continue reading \"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T12:04:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions","datePublished":"2022-09-29T12:04:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/","name":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==","datePublished":"2022-09-29T12:04:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTM3OCM1MTc3NDY4IzUwMDA3NjYxMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-board-member-timothy-springer-ph-d-wins-lasker-award-for-seminal-discovery-of-key-adhesion-molecules-that-mediate-immune-cell-interactions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690181"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690181\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}